Last reviewed · How we verify
Lambda Therapeutic Research Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Denosumab-Ref | Denosumab-Ref | phase 3 | RANKL inhibitor (monoclonal antibody) | RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) | Oncology, Bone Metabolism |
Therapeutic area mix
- Oncology, Bone Metabolism · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Amgen · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 shared drug class
- Luye Pharma Group Ltd. · 1 shared drug class
- Prince of Wales Hospital, Shatin, Hong Kong · 1 shared drug class
- Seoul National University Bundang Hospital · 1 shared drug class
- Swiss Cancer Institute · 1 shared drug class
- University of Alabama at Birmingham · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Lambda Therapeutic Research Ltd.:
- Lambda Therapeutic Research Ltd. pipeline updates — RSS
- Lambda Therapeutic Research Ltd. pipeline updates — Atom
- Lambda Therapeutic Research Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Lambda Therapeutic Research Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lambda-therapeutic-research-ltd. Accessed 2026-06-10.